Regulatory Status Guide
How PepStack classifies peptide regulatory status using authoritative FDA and clinical trial sources. These labels are research context, not sourcing or treatment guidance.
Our Classification Methodology
PepStack assigns regulatory status labels based on direct verification against official FDA databases, FDA enforcement pages, and ClinicalTrials.gov records. We do not rely on marketing claims, vendor descriptions, or informal market terminology.
Each classification is tied to a specific source document (FDA label, approval letter, or clinical trial record) and includes the date of last verification.
Regulatory Classifications
An official FDA label, approval letter, or FDA press/approval source was located for a U.S. human drug product containing the peptide active ingredient. This is a formal regulatory category tied to FDA approval materials, not marketing claims.
A current ClinicalTrials.gov record was located for the peptide candidate; no U.S. FDA approval was identified in the sources used. A registered clinical trial is evidence of active development, not market legality or approval.
FDA lists the substance on its page of bulk drug substances for compounding that may present significant safety risks, either in Category 2 under interim compounding policies or in the "other bulk drug substances" section. This is more precise than calling a substance "banned" or "unregulated."
The substance is on FDA's Category 2 bulk drug substances list, meaning the FDA has evaluated it and determined it presents safety or efficacy concerns that restrict its use in pharmacy compounding. This does not mean the substance is "banned" outright, but compounding pharmacies may not legally produce it for human use under current FDA guidance.
The substance is currently classified under one FDA category but has been publicly identified for potential reclassification (e.g., from Category 2 to Category 1). This reflects announced policy intent that has not yet been finalized through formal FDA rulemaking or Federal Register publication.
The substance is eligible for compounding by licensed 503A (patient-specific prescription) or 503B (outsourcing facility) pharmacies under current FDA regulations. A valid prescription from a licensed prescriber is typically required.
This peptide has not been independently evaluated against FDA databases for this project. It may or may not have regulatory status -- the absence of a classification does not imply approval or safety.
Terms We Avoid
"Unregulated"
Not used as a primary status label. The term is ambiguous in peptide markets. PepStack instead maps substances to explicit FDA-relevant categories such as approved, investigational, or FDA-flagged safety-risk-for-compounding.
"FDA-banned"
Not used as a primary status label. FDA pages relevant to peptides more often concern approval status, warning/enforcement actions, and compounding safety-risk designations rather than a peptide-only "banned list."
Authoritative Sources
Master official FDA resource list.
https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
Official approval/label lookup starting point.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
Authoritative source for peptide substances FDA says may present significant safety risks for compounding.
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Regulatory warning context for unapproved semaglutide/tirzepatide/retatrutide products.
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Current enforcement context for non-FDA-approved GLP-1 APIs.
https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
Current-trial verification for investigational candidates.
https://clinicaltrials.gov/
Disclaimer: PepStack provides regulatory status classifications for educational and research purposes only. These classifications reflect the status found in official sources at the time of verification and may change. PepStack does not provide medical advice, diagnosis, or treatment recommendations. Consult the linked FDA sources directly for the most current regulatory information.